Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| PYXS | SC 13G/A | neutral | 4/10 | GordonMD Global Investments LP and affiliated entities filed an amended Schedule 13G on October 9, 2026, disclosing bene | Oct 9, 2026 |
| LNAI | 8-K | bearish | 6/10 | Lunai Bioworks submitted a formal request to Nasdaq on October 9, 2026, asking for an immediate trading suspension in it | Oct 9, 2026 |
| EXOZ | 8-K | neutral | 2/10 | EXOZYMES INC. filed an 8-K attaching an investor presentation dated October 6, 2026, that may be provided to investment | Oct 9, 2026 |
| BIAF | 424B5 | bearish | 7/10 | bioAffinity Technologies is raising approximately $4M in net proceeds through a registered direct offering of 116,545 co | Oct 9, 2026 |
| BIAF | 424B5 | neutral | 4/10 | bioAffinity Technologies filed a 424B5 prospectus supplement reducing the available shares under its ATM agreement with | Oct 9, 2026 |
| ZYME | 144 | neutral | 2/10 | Adam Schayowitz, an officer of Zymeworks Inc., filed a Form 144 on October 9, 2026, indicating intent to sell 13,832 sha | Oct 9, 2026 |
| SXTC | 424B5 | bearish | 7/10 | China SXT Pharmaceuticals is conducting a dilutive offering of up to 8,000,000 units (plus an over-allotment option for | Oct 9, 2026 |
| JAZZ | 8-K | neutral | 2/10 | Jazz Pharmaceuticals disclosed that EVP and Chief Commercial Officer Samantha Pearce plans to retire, effective upon app | Oct 9, 2026 |
| EPRX | 6-K | neutral | 4/10 | Eupraxia announced that three abstracts from its Phase 1b/2 RESOLVE trial of EP-104GI for eosinophilic esophagitis have | Oct 9, 2026 |
| ATOS | 8-K | neutral | 4/10 | Atossa Therapeutics entered into a Contingent Value Rights (CVR) Agreement, declaring a dividend of one CVR per share of | Oct 9, 2026 |
| ACIU | 3 | neutral | 2/10 | Thomas Graney filed a Form 3 initial statement of beneficial ownership with the SEC, reporting 12,959 common shares and | Oct 9, 2026 |
| QNCX | 8-K | bullish | 7/10 | Quince Therapeutics has completed its transformation into IRulya Therapeutics, executing a full leadership overhaul with | Oct 9, 2026 |
| GHRS | 6-K | neutral | 2/10 | GH Research PLC announced via Form 6-K that it will present data from its GH001-TRD-201 and GH001-BD-202 clinical trials | Oct 9, 2026 |
| URGN | 144 | neutral | 2/10 | Chris Degnan, an officer of UroGen Pharma, filed a Form 144 on October 9, 2026, indicating intent to sell 2,202 ordinary | Oct 9, 2026 |
| RNA | 8-K/A | neutral | 2/10 | Atrium Therapeutics filed an 8-K/A to correct the share count disclosed in its October 8, 2026 original 8-K regarding a | Oct 9, 2026 |
| CTY | S-1/A | neutral | 5/10 | City Therapeutics, a clinical-stage RNAi biotech founded in July 2023, filed its S-1/A for an IPO of 9,722,222 shares at | Oct 9, 2026 |
| ATHE | 6-K | neutral | 2/10 | Alterity Therapeutics filed a 6-K announcing that CEO David Stamler will present at the Canaccord Genuity Drug and Devic | Oct 9, 2026 |
| RTSN | EFFECT | bullish | 7/10 | The SEC declared effective Retension Pharmaceuticals' S-1 registration statement for its initial public offering of 3,30 | Oct 9, 2026 |
| BGMS | EFFECT | neutral | 4/10 | Bio Green Med Solution, Inc. received SEC effectiveness for its S-4 registration (File No. 333-296815) on October 8, 202 | Oct 9, 2026 |
| GOSS | SC 13D/A | bearish | 5/10 | D. E. Shaw filed Amendment No. 5 to its Schedule 13D for Gossamer Bio, primarily to correct an understatement of voting | Oct 8, 2026 |
| AMGN | COURT-RULING | bearish | 6/10 | The First Circuit partially reversed the district court's dismissal of a wrongful death suit against Amgen concerning it | Oct 8, 2026 |
| ATTO | 3/A | neutral | 1/10 | This is a purely administrative amendment (3/A) to a Form 3 initial beneficial ownership filing. The amendment corrects | Oct 8, 2026 |
| ATTO | 3/A | neutral | 2/10 | This is an administrative amendment (Form 3/A) filed by Steven Chan, CFO of Attovia Therapeutics, correcting the reporti | Oct 8, 2026 |
| AVBP | SC 13D/A | bearish | 5/10 | OrbiMed Advisors filed Amendment No. 2 to its Schedule 13D for ArriVent BioPharma (AVBP), reporting a reduction in benef | Oct 8, 2026 |
| RTSN | 3 | neutral | 2/10 | Alexander Duke Schwartz filed a Form 3 initial statement of beneficial ownership upon becoming CFO of Retension Pharmace | Oct 8, 2026 |
| RTSN | 3 | neutral | 2/10 | Paul Sweetnam filed a Form 3 initial statement of beneficial ownership upon becoming Chief Scientific Officer of Retensi | Oct 8, 2026 |
| RTSN | 3 | neutral | 2/10 | Alison D. Schecter filed an initial Statement of Beneficial Ownership (Form 3) with the SEC, reporting her appointment a | Oct 8, 2026 |
| RTSN | 3 | neutral | 2/10 | Analysis based on filing metadata only, document content was unavailable. This is a Form 3 filing for Retension Pharmace | Oct 8, 2026 |
| RTSN | 3 | neutral | 2/10 | Eric Keller, CEO of Retension Pharmaceuticals, filed an initial statement of beneficial ownership (Form 3), disclosing 4 | Oct 8, 2026 |
| RTSN | 3 | neutral | 2/10 | Sabine Bisson, the Chief Operating Officer of Retension Pharmaceuticals, filed a Form 3 initial statement of beneficial | Oct 8, 2026 |